Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
41 hedge funds and large institutions have $15.9M invested in Regulus Therapeutics in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 9 closing their positions.
73% more call options, than puts
Call options by funds: $373K | Put options by funds: $216K
0.44% less ownership
Funds ownership: 3.08% → 2.64% (-0.44%)
7% less funds holding
Funds holding: 44 → 41 (-3)
15% less capital invested
Capital invested by funds: $18.7M → $15.9M (-$2.88M)
27% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 11
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$688K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$139K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$59.7K |
| 4 |
Morgan Stanley
New York
|
+$47.5K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$28.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$263K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$179K |
| 3 |
FWM
Focused Wealth Management
Newburgh,
New York
|
-$163K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$104K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$76.5K |
RGLS Hedge Fund Activity: Q3 2021 in Review
41 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q3 2021, worth a combined $15.9M — down 15% from $18.7M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of RGLS and 6 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 8 added.
The largest buyer was Endurant Capital Management, adding an estimated $688K. The largest seller was Acadian Asset Management, cutting an estimated $263K.
- 41 institutional investors held Regulus Therapeutics (RGLS) as of Q3 2021, down from 44 in Q2 2021.
- Funds reported $15.9M of Regulus Therapeutics stock for Q3 2021, down 15% quarter-over-quarter.
- 6 funds opened new Regulus Therapeutics positions in Q3 2021 and 9 closed out, a net change of -3 holders.
- The largest Regulus Therapeutics buyer in Q3 2021 was Endurant Capital Management, an estimated $688K added.
- The largest Regulus Therapeutics seller in Q3 2021 was Acadian Asset Management, an estimated $263K sold.
Based on aggregated 13F filings for Q3 2021.